Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tuspetinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 175,273Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose Reports Third Quarter 2025 Results
    Aptose Reports Third Quarter 2025 Results

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187912/35575/en/Aptose-Reports-Third-Quarter-2025-Results.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH
    Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179367/35575/en/Aptose-Tuspetinib-Clinical-Data-from-Ongoing-TUSCANY-Trial-in-Newly-Diagnosed-AML-Selected-for-Presentation-at-the-2025-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Aptose’s Tuspetinib Excels with Standard Care in AML Patients
    Aptose’s Tuspetinib Excels with Standard Care in AML Patients

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167802/35575/en/Aptose-s-Tuspetinib-Exceeds-Expectations-When-Combined-with-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Aptose, Hanmi Pharma Extend Loan For Tuspetinib In Aml Triplet
    Aptose, Hanmi Pharma Extend Loan For Tuspetinib In Aml Triplet

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153823/35575/en/Aptose-and-Hanmi-Pharmaceutical-Extend-Loan-Agreement-to-Continue-Development-of-Tuspetinib-in-Triplet-Therapy-for-AML.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Aptose's Tuspetinib boosts AML treatment in Phase 1/2 Trial
    Aptose's Tuspetinib boosts AML treatment in Phase 1/2 Trial

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/18/3134929/35575/en/Aptose-Reports-Early-Data-Demonstrating-Tuspetinib-Improves-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML-in-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Aptose Picks Ernst & Young Global Limited as New Auditor
    Aptose Picks Ernst & Young Global Limited as New Auditor

    01 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/01/3125714/35575/en/Aptose-Selects-Ernst-Young-Global-Limited-as-its-New-Independent-Auditor-and-Calls-Reconvened-Meeting-of-its-Shareholders.html

    GLOBENEWSWIRE
    01 Aug 2025
    Share Share